Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

UK Research and Innovation, Cancer Research UK and industry are investing more than £11 million in an Oxford-led artificial intelligence (AI) research programme to improve the diagnosis of lung cancer and other thoracic diseases.

Professor Fergus Gleeson at the University of Oxford will lead on a programme of research focusing on accelerating pathways for the earlier diagnosis of lung cancer. Lung cancer is the biggest cause of cancer death in the UK and worldwide, with £307 million/year cost to the NHS in England. The earlier that lung cancer is diagnosed, the more likely that treatment will be successful but currently only 16% patients are diagnosed with the earliest stage of the disease. To address this clinical problem, NHS England is launching a £70 million lung cancer screening pilot programme at 10 sites*.

To improve patient care beyond the current screening guidelines, a team of academics from Oxford University, Nottingham University, and Imperial College London; NHS clinicians from Oxford University Hospitals NHS Trust, Nottingham University Hospitals NHS Trust, the Royal Marsden Hospital, the Royal Brompton Hospital, and University College London Hospitals NHS Foundation Trust; and the Roy Castle Lung Cancer Foundation will join forces with three leading industrial partners (Roche Diagnostics, GE Healthcare, Optellum).

The full story is available on the University of Oxford website

Similar stories

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

National consortium to study threats of new SARS-CoV-2 variants

Coronavirus COVID-19 General Research

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

Retirement of Professor Peter Brown

General

This month sees the retirement of Professor Peter Brown as Director of the Medical Research Council Brain Network Dynamics Unit at the University of Oxford.

Immunology preprint reviews launched in Nature Reviews Immunology

General Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

General Research

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’